Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0381 | 1 | 1 |
Leishmania major | ion transport protein-like protein | 0.0323 | 0.8354 | 0.5 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.083 | 0.083 |
Schistosoma mansoni | hypothetical protein | 0.0381 | 1 | 1 |
Onchocerca volvulus | 0.0213 | 0.5254 | 0.5 | |
Schistosoma mansoni | calcium-activated potassium channel | 0.0363 | 0.9477 | 0.9477 |
Toxoplasma gondii | kinesin motor domain-containing protein | 0.0026 | 0 | 0.5 |
Echinococcus multilocularis | small conductance calcium activated potassium | 0.0381 | 1 | 1 |
Schistosoma mansoni | nAChR subunit (ShAR1-alpha-like) | 0.0213 | 0.5254 | 0.5254 |
Onchocerca volvulus | 0.0213 | 0.5254 | 0.5 | |
Brugia malayi | Cation transporter family protein | 0.0213 | 0.5254 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0213 | 0.5254 | 0.5254 |
Schistosoma mansoni | calcium-activated potassium channel | 0.0381 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0172 | 0.4121 | 0.4121 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.083 | 0.158 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.083 | 0.083 |
Trypanosoma cruzi | ion transport protein, putative | 0.0323 | 0.8354 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.083 | 0.083 |
Loa Loa (eye worm) | hypothetical protein | 0.0172 | 0.4101 | 0.4101 |
Plasmodium falciparum | kinesin-5 | 0.0026 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0213 | 0.5254 | 0.5254 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.083 | 0.083 |
Onchocerca volvulus | 0.0213 | 0.5254 | 0.5 | |
Plasmodium vivax | kinesin-5 | 0.0026 | 0 | 0.5 |
Echinococcus granulosus | kinesin family 1 | 0.0198 | 0.4844 | 0.4377 |
Schistosoma mansoni | nAChR subunit (ShAR1-beta-like) | 0.0213 | 0.5254 | 0.5254 |
Echinococcus multilocularis | kinesin family 1 | 0.0198 | 0.4844 | 0.4377 |
Loa Loa (eye worm) | hypothetical protein | 0.0197 | 0.482 | 0.482 |
Giardia lamblia | Kinesin-5 | 0.0026 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0191 | 0.4653 | 0.4653 |
Entamoeba histolytica | kinesin, putative | 0.0026 | 0 | 0.5 |
Trypanosoma cruzi | ion transport protein, putative | 0.0323 | 0.8354 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.